Zhuang Hongqing, Zhao Xianzhi, Zhao Lujun, Chang Joe Y, Wang Ping
Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, and Tianjin Lung Cancer Center, Tianjin, People's Republic of China.
Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Drug Des Devel Ther. 2014 May 29;8:667-75. doi: 10.2147/DDDT.S61977. eCollection 2014.
The combination of radiotherapy and targeted therapy is an important approach in the application of targeted therapy in clinical practice, and represents an important opportunity for the development of radiotherapy itself. Numerous agents, including epidermal growth factor receptor, monoclonal antibodies, tyrosine kinase inhibitors, and antiangiogenic therapies, have been used for targeted therapy. A number of studies of radiotherapy combined with targeted therapy in non-small-cell lung carcinoma have been completed or are ongoing. This paper briefly summarizes the drugs involved and the important related clinical research, and indicates that considerable progress has been made with the joint efforts of the two disciplines. Many issues, including drug selection, identification of populations most likely to benefit, timing of administration of medication, and side effects of treatment require further investigation. However, further fundamental research and accumulation of clinical data will provide a more comprehensive understanding of these therapies. Targeted therapy in combination with radiotherapy has a bright future.
放射治疗与靶向治疗相结合是靶向治疗在临床实践中应用的重要途径，也是放射治疗自身发展的重要契机。众多药物，包括表皮生长因子受体、单克隆抗体、酪氨酸激酶抑制剂和抗血管生成疗法，已被用于靶向治疗。多项关于非小细胞肺癌放射治疗联合靶向治疗的研究已经完成或正在进行。本文简要总结了所涉及的药物及重要的相关临床研究，并指出两学科共同努力已取得了相当大的进展。许多问题，包括药物选择、最可能受益人群的识别、给药时机以及治疗副作用等，都需要进一步研究。然而，进一步的基础研究和临床数据积累将使人们对这些疗法有更全面的认识。靶向治疗联合放射治疗前景光明。
